zinc supplementation and non-alcoholic fatty liver disease
- Conditions
- onalcoholic fatty liver.
- Registration Number
- IRCT20181005041238N1
- Lead Sponsor
- Esfahan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
Patients aged up to 18 years and more
an involvement of 33% of liver tissue with fats by ultrasound
BMI between 25-35
An unwillingness of patients to participate in the study
pregnancy
breastfeeding
travel for more than 2 weeks
smokers
iron supplementation users
diabetes patients
alcohol consumption
patients with hepatitis B and C
hemochromatosis
Wilson's disease
patients with heart failure
kidney disease
autoimmunity
hypothyroidism or hyperthyroidism
Grade3 fatty liver patients
athletes
patients with any malabsorption
Weight changes over 5 kg In the last 3 months
follow a diet plan and certain physical activity
use of hepatotoxic drugs such as blockers, calcium channel, high doses of synthetic estrogens, methotrexate, chloroquine, tamoxifen, non-steroid anti-inflammatory drugs, amiodarone, statins and fibers
consumption drugs such as cefalexin, tetracycline and its derivatives, ceftibuten, deferiprone, antibiotics Quinolone is consumed
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method